Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma
Janice Ahn(West Virginia University), Flavia Rosado(Mayo Clinic), Ryan Okal(West Virginia University), Matthew B. Smolkin(West Virginia University), Jeffrey A. Vos(West Virginia University), Abraham S. Kanate(HonorHealth)
Cited by 70
Related Papers
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2020|278
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
|Blood|2015|273
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
|Blood|2017|247
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183
R‐<scp>CHOP </scp><i>versus</i> dose‐adjusted R‐<scp>EPOCH</scp> in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis
|British Journal of Haematology|2017|101